Omega Funds
Venture capitalActively deployingBoston · Seed–Late Stage · 17 people tracked
Investment thesis
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Team · 17 people
from public directories
What they invest in
from 19 of 20 portfolio companiesBiotech ×15Medical Devices ×7Healthtech ×5Deep Tech ×3AI & Machine Learning ×2Digital Health ×2Advanced Manufacturing ×1Cybersecurity ×1
HQs:United States×17Colombia×1
Investments · 20 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 12024 · 42023 · 12022 · 12021 · 12020 · 12019 · 12018 · 12016 · 115 dated
Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription.
Digital HealthHealthtechMedical DevicesIrvine, US
Edward Damiano(Executive Officer, Director)Gilbert Clarke(Executive Officer)Edward Raskin(Executive Officer, Director)Mike Roskino(Executive Officer)Agustin Mohedas(Director)Jeff Hitchcock(Director)
Board seatFrancesco Draetta· per SEC Form D · $101.8M raise · filed Sep 2023
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
Andreas Muehler(Executive Officer)Daniel Vitt(Executive Officer, Director)inJASON TARDIO(Executive Officer)GLENN WHALEY(Executive Officer)INDERPAL SINGH(Executive Officer)Patrick Walsh(Executive Officer)
Board seatVincent Ossipow· per SEC Form D · $60M raise · filed Oct 2022
Co-investorsBayern Kapitalbmp VenturesFund+Pontifax Venture Capital
Nuvation Bio is a global oncology company developing and commercializing novel therapies for difficult-to-treat cancers, targeting indications where conventional treatments have failed.
BiotechHealthtechNew York, US
David Hung(Founder, President & Chief Executive Officer)
Board seatMichelle DoigClaudio Nessi· per SEC Form D · $275.3M raise · filed Oct 2020
Co-investorsAisling CapitalDecheng CapitalEcoR1 CapitalVertex Ventures China
BiotechBoston, US
Mary DiBiase(Executive Officer)Christophe Arbet-Engels(Executive Officer)David Kirske(Executive Officer)John Volpone(Executive Officer)Mark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)
Board seatClaudio Nessi· per SEC Form D · $50.5M raise · filed May 2017
Co-investorsPolaris Partners
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)
Co-investorsAtlas VentureLightspeed Venture PartnersVida VenturesTenmileAbingworthBiotechnology Value Fund
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Zachary Hornby(Chief Executive Officer)
Co-investorsNovo HoldingsFrazier Life SciencesJeito CapitalNorwest Venture Partners
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Board seatClaudio Nessi· per SEC Form D · $110.7M raise · filed Jan 2026
Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life Sciences+2 more
South San Francisco, US
Board seatOtello Stampacchia· per SEC Form D · $117M raise · filed Mar 2021
Co-investorsFrazier Life Sciences
BiotechCambridge, US
Praveen Tipirneni(Executive Officer, Director)
BoardAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)
Board seatMichelle Doig· per SEC Form D · $37.5M raise · filed Jan 2026
Co-investorsAtlas VentureBain Capital Life SciencesJanus Henderson InvestorsLAVvenBio Global StrategicvenBio Partners+1 more
BiotechVancouver
Frank Perabo(Executive Officer)Franklin Berger(Director)Raymond Andersen(Executive Officer, Director)Scott Requadt(Director)Paul Cossum(Executive Officer)David Wood(Executive Officer)
Board seatOtello Stampacchia· per SEC Form D · $36M raise · filed Aug 2019
Co-investorsClarus
BiotechBoston, US
Jotin Marango(Executive Officer)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Sergio Santillana(Executive Officer)Michelle Zhang(Executive Officer)
Board seatOtello Stampacchia· per SEC Form D · $75M raise · filed Jul 2025
Co-investorsAtlas VentureBiotechnology Value FundForesite CapitalOrbiMedRTW Investments L.P.
BiotechWaltham, US
Timothy Springer(Director)Praveen Tiprirneni(Executive Officer, Director)Robert Farrell(Executive Officer)
BoardBarbara Dalton(Director)Ramy Farid(Director)Kevin Bitterman(Director)in
Board seatOtello Stampacchia· per SEC Form D · $80M raise · filed Oct 2018
Co-investorsAtlas VenturePolaris Partners
BiotechBoston, US
Adam Friedman(Executive Officer, Director)Gary Glick(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)
Board seatOtello Stampacchia· per SEC Form D · $150M raise · filed Jul 2024
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestVida Ventures+2 more
Spiro Medical develops an implantable neuromodulation system using targeted spinal nerve stimulation to modulate respiratory function in patients with severe, uncontrolled asthma who have not responded to conventional treatments.
BiotechHealthtechMedical DevicesBelleair Bluffs, US
Rinda Sama(Executive Officer)
BoardBrian Mooney(Director)
Board seatClaudio Nessi· per SEC Form D · $69.1M raise · filed Jan 2026
Co-investorsAndera PartnersSupernova Invest
BiotechPalo Alto, US
Idan Elmelech(Executive Officer)Pedro Beltran(Executive Officer)Frank McCormick(Director)Neil Kumar(Director)Eli Wallace(Executive Officer)Raymond Kelleher(Director)
Board seatMichelle Doig· per SEC Form D · $200M raise · filed May 2024
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)in
Board seatFrancesco DraettaOtello Stampacchia· per SEC Form D
Co-investorsAndreessen HorowitzVida Venturesabrdn plcBiotechnology Value FundForesite CapitalHillhouse Investment+1 more
XII Medical develops neuromodulation therapies for treating obstructive sleep apnea, focusing on simplifying treatment options and improving patient outcomes.
Deep TechDigital HealthHealthtechMedical DevicesUnion City, US
Garrett Schwab(Chief Executive Officer)Shane Kreidel(Secretary and Chief Financial Officer)inZachary Eisen(Director)
BoardDuke Rohlen(Director)inJD Friedland(Director)
Board seatSaoussen Ben Halima· per SEC Form D
Co-investorsAPERTURE Venture PartnersBroadview VenturesCincyTechIntuitive VenturesJobsOhio VenturesAjax Health
GelSight develops high-resolution tactile imaging and surface metrology technology for measuring and analyzing surface properties in manufacturing.
Advanced ManufacturingAI & Machine LearningDeep TechHardwareWaltham, US
Micah K Johnson(Executive Officer, Director)Janos Rohaly(Executive Officer)Edward Adelson(Director)Micah Kimo Johnson(Executive Officer, Director)William J. Yost(Executive Officer, Director)
Co-investorsAnzu PartnersScout VenturesScout Ventures
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Co-investorsAtlas VentureNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime Capital5AM Ventures+1 more
Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.
CybersecurityEnterprise SoftwareSaaSBogotá, CO
Pablo Rojas(Founder)in
Co-investorsNovartis Venture FundY CombinatorForbionGlilot Capital PartnersYK Bioventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
IPOs and acquisitions across the tracked portfolioBeta Bionics, IncNASDAQ: BBNXImmunicNASDAQ: IMUXNuvation BioNYSE: NUVBX4 PharmaceuticalsNASDAQ: XFOR
Portfolio news
latest coverage across their companiesNuvation Bio · aromatherapynaturals.com · Aug 22, 2026
Immunic · themarketsdaily.com · Aug 19, 2026
Alveus Therapeutics · fiercebiotech.com · Aug 12, 2026
Beta Bionics, Inc · tradingview.com · Aug 11, 2026
Caldera Therapeutics, Inc. · businesswire.com · Jul 29, 2026
Calliotx · funderintel.com · Jul 16, 2026
nChroma Bio · contagionlive.com · Jun 25, 2026
Third Arc Bio · allsci.com · Feb 4, 2026
Frequently asked questions
- What stage does Omega Funds invest at?
- Omega Funds invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does Omega Funds focus on?
- Omega Funds focuses on Biotech, Medical Devices.
- Where is Omega Funds located?
- Omega Funds is headquartered in Boston, US.
Media · Podcasts & interviews
featuring the team#OptimumTV meets Omega Funds Otello Stampacchia to discuss the #lifescience investor outlook on 2026
Optimum Strategic Communications · Otello Stampacchia
Extrait Conférences BIOTECH MEDTECH HEALTHTECH LeZoom19H : Vincent Ossipow, Partner chez Omega Funds
Biotech Finances · Vincent Ossipow
Co-investors · 21
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
Avoro Capital Advisors is an investment firm focused on healthcare and life sciences, pursuing scientific breakthroughs that address unmet medical needs.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
▶9 more co-investors
RA CapitalOUP (Osage University Partners)The Column GroupPfizer Venture InvestmentsSV Health InvestorsFrazier Healthcare PartnersHatteras Venture PartnersRoche Venture FundCofounders Capital
Firms observed investing alongside Omega Funds, from public investor directories. Shared companies are the overlap with Omega Funds's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.
JSTAR Capital Investments is a healthcare-focused investment firm backing medical technology companies, providing capital and expert guidance to advance patient care and address global healthcare challenges.